JAZZ - Jazz Pharma Zymeworks announce 84% overall survival at 18 months from phase 2 trial testing Zanidatamab

• Jazz Pharma ( NASDAQ: JAZZ ) and Zymeworks ( NASDAQ: ZYME ) announced tolerability and efficacy results, including the first overall survival data, from a Phase 2 trial testing zanidatamab in combination with chemotherapy, in first-line patients with HER2-expressing metastatic gastroesophageal adenocarcinoma.
• The company said that the preliminary results showed that, at the time of analysis, the median OS had not yet been reached with a median duration of study follow-up of 26.5 months.
• The 18-month overall survival rate was 84%.
• Treatment with zanidatamab also shoowed a confirmed objective response rate of 79%, a disease control rate of 92%, with three patients achieving complete response among 38 response-evaluable patients.
• The company said its looking forward to additional data in 2024 from the ongoing pivotal Phase 3 trial that may support U.S. and global regulatory filings.

For further details see: